Publicaciones en las que participa el autor/a De Andrés F

13

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Autores

De Andrés F, Dorado P, Llerena A, Machín E, Naranjo ME, Peñas-Lledó EM

22

Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

Autores

De Andrés F, Lazalde-Ramos BP, Llerena A, Naranjo ME, Sosa-Macías M, Tarazona-Santos E

33

A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity.

Autores

De Andrés F, Llerena A, Sosa-Macías M

43

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Autores

Céspedes-Garro C, De Andrés F, Fariñas H, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

50

Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations.

Autores

Céspedes-Garro C, De Andrés F, Delgado A, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

54

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Autores

Cobaleda J, De Andrés F, Delgado A, Llerena A, Naranjo ME, Peñas-Lledó EM

59

To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.

Autores

De Andrés F, Hernández F, Llerena A, Terán E

60

Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.

Autores

De Andrés F, Llerena A

61

Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen.

Autores

Alonso I, Arroyo G, De Andrés F, Estévez-Carrizo FE, González-Vacarezza N, Llerena A, Martínez J

62

Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?

Autores

Alves G, De Andrés F, Falcão A., Llerena A, Magalhães P

64

Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.

Autores

Calzadilla LR, De Andrés F, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM

66

CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?

Autores

De Andrés F, Llerena A, Naranjo ME, Ramos BPL, Sosa-Macías M

74

Frequency of CYP2C9 (2, 3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin.

Autores

Castillo-Nájera F, Cuautle-Rodríguez P, De Andrés F, Llerena A, Molina-Guarneros J, Rodríguez-Rivera N

82

High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations.

Autores

Borbón A, De Andrés F, Dorado P, Llerena A, Sarmiento AP